Clinical Trial Update: Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 efficacy and safety study comparing JNJ-32729463 to moxifloxacin in hospitalized community-acquired pneumonia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia

Drugs mentioned

• JNJ-32729463
• Moxifloxacin (moxifloxacin)

Snippet

Sponsor: Furiex Pharmaceuticals, Inc | Conditions: Community-Acquired Bacterial Pneumonia (CABP) | Phase 2 | Status: TERMINATED